Clinical Study

Somatostatin Level In Cystic Fibrosis

Posted Date: Dec 20, 2022

  • Investigator: Jason Winnick
  • Specialties:
  • Type of Study: Observational/Survey

People with cystic fibrosis have very high risk of developing cystic fibrosis related diabetes (CFRD). People who have developed CFRD have reduced insulin secretion after eating leading to high blood sugar. To correct this high blood sugar, people with CFRD are usually treated with insulin. Insulin treatment is relatively inconvenient, and it puts an additional burden on people with CFRD. Somatostatin is a hormone that inhibits insulin secretion, and its blood level usually increases in response to eating a meal. Based on a previous study, blood somatostatin level could be high in people with CFRD. Because somatostatin inhibits insulin secretion, a high somatostatin level could potentially contribute to reduced insulin secretion and increased blood sugar level. This study is designed to confirm if somatostatin secretion is increased in people with CFRD after eating.


We Are Looking For Adults With Cystic Fibrosis, With Or Without Cfrd, And Healthy Controls Ages 18-45.


Cystic Fibrosis, Somatostatin, Endocrinology

For More Information:

Blair Kathleen Hoeting

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.